10.2 Mandatory Queries, Designees & Documentation

10.2 Mandatory Queries, Designees & Documentation

Quick Answer: Illinois prescribers with controlled-substance licenses must register with ILPMP and historically had to document an attempt to access/review the patient’s ILPMP profile before an initial Schedule II narcotic (opioid) prescription, with exceptions for oncology, palliative care, and a ≤7-day hospital ED supply for an acute condition. Public Act 104-0512, effective January 1, 2027, expands that documented attempt to any C-II opioid, any C-IV benzodiazepine, and an initial C-II stimulant. Pharmacists are not given a carbon-copy “query every CII–V before every dispense” statute in the same form—use ILPMP under corresponding responsibility and professional judgment when red flags appear. Designees may help access the system if trained (HIPAA / 42 CFR Part 2) and properly linked.

Section 10.1 covered what ILPMP is and how reporting works. This section is about when a check is legally required, who may perform the click, and what must be written down—the highest-yield PMP distinctions on the Illinois MPJE.

Prescriber Registration Mandate

Each prescriber possessing an Illinois controlled substances license shall register with ILPMP at www.ilpmp.org. Key clarifications:

• EHR/PMPnow integration ≠ registration. Program FAQs state that using an integrated connection does not by itself mean the prescriber is registered on the website.
• IDFPR may take disciplinary action for registration noncompliance (case-by-case).
• PA 104-0512 adds that a prescriber is not subject to criminal liability or professional discipline for failure to register due to technological or electrical failures or operational issues that prevent registration—a narrow tech-failure shield, not a “I never bothered” defense.
• Licensed veterinarians are exempt from registration and prohibited from accessing patient ILPMP information (animals are outside the human PMP design).

Historical Mandatory Query: Initial Schedule II Narcotics

Under 720 ILCS 570/314.5(c-5) as long taught for exams (Public Act 100-0564 framework):

Each prescriber or the prescriber’s designee shall document an attempt to access patient information in ILPMP to assess controlled-substance access when providing an initial prescription for Schedule II narcotics such as opioids, except:

1. Prescriptions for oncology treatment
2. Palliative care
3. A 7-day or less supply provided by a hospital emergency department when treating an acute (historically framed as acute traumatic) medical condition

The attempt to access shall be documented in the patient’s medical record. Hospitals must facilitate designation of a prescriber’s designee for hospital services.

What “document the attempt” means

ILPMP FAQs leave the exact documentation format to prescribers and organizations (note in chart, checkbox in EHR, PMPnow access log plus clinical note, etc.). Exam-correct ideas:

• A silent mental intention is not documentation
• Documentation should show that the clinician (or designee) tried to access/review ILPMP in connection with that prescribing decision
• System downtime should still be handled with organizational policy—do not invent a universal “always skip if busy” exception beyond the statutory carve-outs

What the historical rule is not

Public Act 104-0512 Expansion — Effective January 1, 2027

ILPMP’s official site banner and the enrolled Act state that effective 1/1/2027, Public Act 104-0512 expands checking requirements. Each prescriber or prescriber’s designee shall document an attempt to access and review the patient’s ILPMP profile prior to prescribing:

1. Any Schedule II opioid (not limited to the first-ever opioid for that patient in the historical “initial narcotic” framing for opioids under the new “all C-II opioid” language)
2. Any Schedule IV benzodiazepine
3. An initial Schedule II stimulant prescription

The Act’s text amends 720 ILCS 570/314.5 so the documented attempt applies when providing an initial prescription for any stimulant substances listed in Schedule II and all prescriptions for Schedule II opioids and Schedule IV benzodiazepine, still excepting oncology treatment, palliative care, and a ≤7-day hospital ED supply when treating a medical condition as framed in the amended statute.

Exam timing posture

• If the stem is set before 1/1/2027, apply the historical initial CII narcotic core plus known exceptions (and still know the expansion is coming).
• If the stem is set on/after 1/1/2027 (or asks what PA 104-0512 changes), apply the expanded opioid / benzodiazepine / initial stimulant documented-attempt map.
• This guide teaches both so you are not blindsided by either exam window.

Memory table

Pharmacist Role: Professional Duty vs. Prescriber Statutory Mandate

This is the most important distinction for pharmacy candidates—and the one exam-meta shorthand about “PMP mandatory checks for Schedule II–V” must not oversimplify into a false statute.

What is true for pharmacists

• Pharmacists may and should access ILPMP as authorized dispensers when clinically indicated.
• Using ILPMP is a powerful tool for prospective DUR, abuse/misuse screens, and corresponding responsibility (Section 10.3).
• Daily reporting of CII–V (except testosterone) and drugs of interest is a dispenser statutory duty (Section 10.1).
• Ignoring glaring multi-pharmacy / multi-prescriber opioid patterns without review is poor professional practice and can support federal/state liability theories.

What is not proven as a carbon-copy statutory twin of the prescriber rule

Illinois practice-bank teaching is explicit: the statutory attempt-to-access mandate for initial Schedule II narcotics (and the 2027 expansion) is written as a prescriber (or designee) duty with medical-record documentation—not a blanket rule that “pharmacists must query ILPMP before dispensing every Schedule II–V controlled substance.”

Decision rule for MPJE stems:

1. If the stem asks about issuing/prescribing and documenting an attempt under 314.5 → answer with prescriber/designee mandatory-query rules.
2. If the stem asks about dispensing with red flags → answer with corresponding responsibility, verify, refuse if illegitimate, and use ILPMP as a clinical tool—without inventing a nonexistent “must query every CV gabapentin-wait, gabapentin is drug of interest…” automatic statutory stop for every single fill.
3. If the stem confuses reporting with querying, separate them: report every reportable dispense; query when required by role or when professional judgment demands.

Section 314.5(e) also states that nothing in that section shall be construed to create a requirement that any prescriber, dispenser, or pharmacist request any patient medication disclosure, report any patient activity, or prescribe or refuse to prescribe or dispense any medications—yet that clause does not erase 21 CFR 1306.04 corresponding responsibility. Read both layers.

Designees: Who, Training, Caps, and Oversight

Who may be a website designee

An authorized website designee is a licensed or non-licensed employee of a prescriber’s office or pharmacy who has received training in:

• HIPAA, and
• 42 CFR Part 2 (substance-use disorder confidentiality framework)

Recognized employee types (program FAQ / Rule 2080.205 framing) include:

• Registered nurse (RN)
• Licensed practical nurse (LPN)
• Pharmacy technician
• Student pharmacists
• Certified medical assistant
• Dental hygienist and dental assistant

Operational rules you must memorize

Prescriber and designee both need ILPMP accounts; the supervisor links accounts using State of Illinois license workflow. Email confirmation activates the link.

Pharmacist–tech workflow example

A busy community pharmacy may lawfully train a pharmacy technician as a designee to pull an ILPMP report for the pharmacist’s clinical review. The tech may not independently decide that a high-risk opioid “looks fine” and clear a clinical refusal decision. Final clinical judgment remains with the pharmacist (parallel to DUR conflict resolution rules in Chapter 9).

Documentation Expectations (Prescriber + Pharmacy)

Prescriber side

• Document the attempt to access/review ILPMP in the medical record when a mandatory-query event applies.
• Document clinical rationale when therapy continues despite complex PMP history (oncology exception vs. diversion concern).
• Hospital systems should facilitate designee designation for ED/inpatient workflows where applicable.

Pharmacy side

• When ILPMP review drives a verify / refuse / counsel / naloxone offer decision, document the intervention in the patient profile or clinical notes so the record supports corresponding responsibility.
• Document error corrections and communications with prescribers about fraudulent or misattributed DEA fills.
• Keep designee lists current and re-verified.

Unsolicited “medication shopping” reports

When ILPMP identifies a person with 5 or more prescribers or 5 or more pharmacies (or both) for controlled substances within a 6-month period under the statute’s threshold (without a common electronic file as specified), the program may issue an unsolicited report to prescribers, dispensers, and designees. If an unsolicited report is issued to a prescriber, it must also be sent to the applicable dispensing pharmacy. Treat such reports as red-flag fuel, not automatic proof of crime—still verify clinically.

Institutional Carve-Outs

Section 314.5 is not construed to apply to inpatients or residents at hospitals or other institutions or to institutional pharmacies in the same outpatient-mandate way. Inpatient order for a hospital floor dose is not the classic community “document attempt before writing the outpatient oxycodone” vignette. Discharge and community retail dispensing re-enter the outpatient world of reporting and professional review.

Worked Scenarios

Scenario A — Initial outpatient oxycodone (historical core). Clinic writes first-ever oxycodone for post-op pain. Prescriber or designee accesses ILPMP and documents the attempt in the chart (unless a listed exception applies). Correct.

Scenario B — ED 5-day acute supply. Hospital ED issues a 5-day opioid supply for an acute condition under the statutory ED exception. Mandatory-query exception may apply; still practice safely and report if retail-dispensed.

Scenario C — After 1/1/2027, alprazolam refill. Prescriber issues ongoing C-IV benzodiazepine. Under PA 104-0512, documented attempt/review expectations extend to C-IV benzodiazepine prescriptions as amended—do not answer with “benzos never require a check.”

Scenario D — Pharmacist stem with doctor-shopping pattern. Patient presents oxycodone from three clinics and four pharmacies in 30 days. Pharmacist queries ILPMP, contacts prescribers, and may refuse—this is corresponding responsibility, not proof that a separate “must query every CV cough syrup” statute exists.

Scenario E — Designee password sharing. PIC posts the pharmacy’s ILPMP password on a sticky note. Noncompliant—designees need individual credentials and training.

Common Traps

• Collapsing prescriber mandatory query into pharmacist must query every CII–V always
• Missing the 1/1/2027 expansion drugs (C-II opioids broadly, C-IV benzos, initial C-II stimulants)
• Treating the 7-day ED rule as a universal outpatient opioid days-supply cap
• Forgetting documentation of the attempt
• Unlimited untrained designees or shared passwords
• Ignoring unsolicited reports sent to the pharmacy

Master the prescriber registration + documented attempt map, the 2027 expansion, designee controls, and the careful pharmacist distinction. Section 10.3 converts PMP data into legitimate medical purpose decisions and red-flag action sequences.